Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light therapy eases mouth sores and skin burns in 33,000 cancer patients

NCT ID NCT07054528

Symptom relief Sponsor: Centre Hospitalier de Valenciennes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This real-world study follows 33,000 cancer patients in France using the CareMin650™ device, which shines light on mouth sores and skin burns caused by chemotherapy or radiation. The goal is to see if this light therapy reduces the severity of these painful side effects. Researchers will also ask nurses and doctors how easy the device is to use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CareMin650™ photobiomodulation device
What this could lead to
If successful, this could confirm that light therapy helps prevent and treat painful mouth sores and skin burns from cancer treatment, improving quality of life.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less reliable. The device is already marketed, so this study mainly confirms real-world use rather than proving new benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 33,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2034

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Most patients with cancer or haematological malignancies receiving chemotherapy and presenting with oral mucositis and/or radio- and/or chemo-induced dermatitis will have some form of oral mucositis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any adult patient over 18 years of age * Patient treated with the CareMin650™ photobiomodulation device, as a preventive or curative measure for oral mucositis and/or radiodermatitis induced by chemotherapy (in the broadest sense: includes targeted therapies, immunotherapy) and/or radiotherapy, as part of their routine management for any type of cancer or haematological malignancy, whatever the stage and prognosis of the disease * Information note sent to the patient and record of the patient's or legal representative's (guardian's) non-objection * Membership of a social security scheme Exclusion Criteria: * Pregnant women * Patient with severe cognitive impairment rendering him/her incapable of expressing non-objection to participation in the study. * If the patient is under guardianship or curatorship: objection from the guardian/curator. * Patient with a known allergy to polyurethane * Patient taking part in a clinical study involving medicinal or non-medicinal therapies to treat or prevent oral mucositis or radiodermatitis. * Patients physically unable to apply Ora-Pad and Derma-Pad devices (e.g. limited mouth opening).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced oral mucositis dermatitis neoplasm radiodermatitis stomatitis ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis Oral mucositis (ulcerative) Oral mucositis (ulcerative) due to antineoplastic therapy Oral mucositis (ulcerative) due to radiation

Contacts and locations

Locations

  • Centre Hospitalier de Valenciennes

    Valenciennes, France, 59300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.